Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - Silo Pharma, Inc. has announced a registered direct offering of 2,857,143 shares of common stock at a price of $0.875 per share, along with a concurrent private placement of unregistered warrants to purchase an equal number of shares at an exercise price of $0.75 per share [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $2.5 million before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about October 1, 2025, subject to customary closing conditions [1]. - The unregistered warrants will be immediately exercisable upon issuance and will expire five years from the effective date of the registration statement [1]. Group 2: Regulatory Information - The common stock is being offered under a "shelf" registration statement that was declared effective by the SEC on January 30, 2024 [3]. - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under the Securities Act or applicable state laws [4]. Group 3: Company Overview - Silo Pharma is a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments [1]. - The company addresses underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases, with programs targeting PTSD, fibromyalgia, Alzheimer's disease, and multiple sclerosis [6].